Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody

Cancer Immunology Research

Volumn 3, Issue 3, 2015, Pages 266-277

  Xu, Hong ^a   Cheng, Ming ^a   Guo, Hongfen ^a   Chen, Yuedan ^a   Huse, Morgan ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; GAMMA INTERFERON; GANGLIOSIDE GD2; HUMANIZED 3F8 BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 2; PENTASACCHARIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD3 ANTIGEN; GANGLIOSIDE; GANGLIOSIDE, GD2; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SAFETY; EC50; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOPHARMACOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS; MONOCYTE; MOUSE; NEUROBLASTOMA; NONHUMAN; STROMA; T LYMPHOCYTE ACTIVATION; TUMOR ABLATION; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG SCREENING; IMMUNOLOGY; KNOCKOUT MOUSE; PHYSIOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CELL LINE, TUMOR; CELL PROLIFERATION; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN G; MELANOMA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MONOCYTES; NEUROBLASTOMA; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961537510     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0230-T     Document Type: Article

References (46)

1. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics, and immunotherapy. Nat Rev Cancer 2013;13:397-411.
2. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37.
3. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett 2014;588:288-97.
4. Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 2015;20:1-14. [Epub ahead of print].
5. Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-Cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 2012;30:3264-70.
6. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
7. Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependentcell-mediated cytotoxicity while retaining targeting in vivo. OncoImmunology 2012;1:477-86.
8. Dobrenkov K, Cheung NKV GD2-targeted immunotherapy and radio-immunotherapy. Semin Oncol 2014;41:589-612.
9. Rosenberg SA Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 2011;8:577-85.
10. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8.
11. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS-and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 2010;107:12605-10.
12. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763-71.
13. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, et al. Strictly target cell-dependent activation of T cells by bispecific singlechain antibody constructs of the BiTE class. J Immunother 2007; 30:798-807.
14. + immune cells contribute to the TGN1412-triggered cytokine response. J Immunol 2014;192:2091-8.
15. Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol 2004;4:403-7.
16. Adair JR, Athwal DS, Bodmer MW, Bright SM, Collins AM, Pulito VL, et al. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Human Antibodies Hybridomas 1994;5:41-7.
17. Lum LG, Thakur A. Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs 2011;25:365-79.
18. Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009;32: 452-64.
19. Garber K. Bispecific antibodies rise again. Nat Rev Drug Discov 2014;13:799-801.
20. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012;503:255-68.
21. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010;23:221-8.
22. Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using a IgG-scFv bispecific antibody with high affinity for GD2 and anti-DOTA metal complex. Mol Cancer Ther 2014;13:1803-12.
23. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010;184:1968-76.
24. Sorkin LS, Otto M, Baldwin WM III, Vail E, Gillies SD, Handgretinger R, et al. Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 2010;149: 135-42.
25. Cheng M, Ahmed M, Xu H, Cheung NK. Structural design of disialoganglio side GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer 2015;136:476-86.
26. Law CL, Hayden-Ledbetter M, Buckwalter S, McNeill L, Nguyen H, Habecker P, et al. Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR-CD3 complex. Int Immunol 2002;14:389-400.
27. -/- mice: a promising model for studying human disease. Arthritis Rheum 2011;63:2764-73.
28. Rahir G, Moser M. Tumor micro environment and lymphocyte infiltration. Cancer Immunol Immunother 2012;61:751-9.
29. Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 2012;59:1198-205.
30. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012;4:182-97.
31. Textor A, Listopad J, Wuhrmann LL, Perez C, Kruschinski A, Chmielewski M, et al. Efficacy of CAR T cell therapy in large tumors relies upon stromal targeting by IFNγ. Cancer Res 2014;74:6796-805.
32. Eastwood D, Bird C, Dilger P, Hockley J, Findlay L, Poole S, et al. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol 2013;76:299-315.
33. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
34. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human Ig G. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989;143:2595-601.
35. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-11.
36. Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered Fcgamma R binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 2013;5:896-903.
37. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608.
38. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineeredto coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
39. Jung ST, Kang TH, Kelton W, Georgiou G. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol 2011;22:858-67.
40. Basu EM, Kushner B, Modak S, Roberts S, Feng Y, Tran H, et al. Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors. Advances in Neuroblastoma Research 2014. Cologne (2014), p. POC034.
41. Ahmed M, Goldgur Y, Hu J, Guo HF, Cheung NK. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS ONE 2013;8:e63359.
42. Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 1987;47:1229-33.
43. Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H. Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer 2004;108:725-32.
44. Eissler N, Mysliwietz J, Deppisch N, Ruf P, Lindhofer H, Mocikat R. Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy. Mol Med 2013;19:54-61.
45. Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res 2012;72:3958-66.
46. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127: 2209-21.